Trending

ASH

As rituximab biosimilars close in, Roche showcases Gazyva superiority

As rituximab biosimilars close in, Roche showcases Gazyva superiority

Roche faces competition against its blockbuster haematology drug

X

As rituximab biosimilars close in, Roche showcases Gazyva superiority

https://pharmaphorum.com/news/rituximab-biosimilars-close-roche-showcases-gazyva-superiority/

Spark reassures on safety of haemophilia gene therapy

Spark reassures on safety of haemophilia gene therapy

Study of nine patients produce encouraging results

X

Spark reassures on safety of haemophilia gene therapy

https://pharmaphorum.com/news/spark-reassures-safety-haemophilia-gene-therapy/

CAR-Ts to take centre stage at ASH haematology congress

CAR-Ts to take centre stage at ASH haematology congress

Haematology is one of the most exciting areas in drug development today, with waves of new treatments emerging

X

CAR-Ts to take centre stage at ASH haematology congress

https://pharmaphorum.com/news/car-ts-take-centre-stage-haematology-congress/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com